Testosterone intake in supportive care patients: impact on quality of life.
EU CTIS ID: 2025-522023-10-00
What this study is testing
To evaluate the impact of testosterone supplementation on the quality of life of male patients in best supportive care with no therapeutic options left and who do not wish to be reanimated.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male hypogonadal cancer patient with total testosterone < 231 ng/dl receiving best supportive care with no further therapeutic options and who do not wish to be reanimated.
- Age ≥ 18 years old
- Patient able to understand the patient information sheet and able to sign the Informed Consent form (ICF) prior to any study related procedure
You likely can't join if
- Untreated relapsed or metastatic prostate cancer, given the risk of epiduritis.
- Known hypersensitivity reactions to the study drug or to any excipients
- Known allergies to peanuts or soya.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.